Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, August 2004, p. 3080-3085, Vol. 48, No. 8
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.8.3080-3085.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Novel Polymorphisms in mec Genes and a New mec Complex Type in Methicillin-Resistant Staphylococcus aureus Isolates Obtained in Rural Wisconsin
Sanjay K. Shukla,1* Srinivas V. Ramaswamy,2 Jennifer Conradt,1 Mary E. Stemper,3 Robert Reich,2 Kurt D. Reed,1,3 and Edward A. Graviss2
Molecular Microbiology Laboratory, Marshfield Clinic Research Foundation,1
Marshfield Laboratories, Marshfield, Wisconsin,3
Department of Pathology, Baylor College of Medicine, Houston, Texas2
Received 27 January 2004/
Returned for modification 8 March 2004/
Accepted 21 April 2004

ABSTRACT
We determined allelic polymorphisms in the
mec complexes of
524 methicillin-resistant
Staphylococcus aureus isolates by
partial or complete sequencing of three
mec genes,
mecA, mecI,
and
mecR1. The isolates had been collected over a 10-year period
from patients living in rural Wisconsin, where the use of antibiotics
was expected to be lower than in the bigger cities. Of the 18
mutation types identified, 16 had not been described previously.
The five most common mutations were a mutation 7 nucleotides
(nt) upstream from the start site (G

T) in the
mecA promoter
(34.7%), an E246G change encoded by
mecA (2.2%), a cytosine
insertion at codon 257 in
mecA (13.2%), an N121K change encoded
by
mecI (7.8%), and a major
mecI-
mecR1 deletion designated as
a class B1
mec complex deletion type (25.4%). There was a high
degree of conservation of the amino acid sequence of MecR1.
Strains with the same mutations had variable resistance to oxacillin,
and the median MIC for isolates that harbored the 7-nt-upstream
mutation was lower than that for strains harboring other mutations.
Our data suggest that the
mecA promoter mutation plays a more
important role in determining methicillin resistance than mutations
in
mecI and
mecA do. Eighty-five percent of the tested isolates
(
n = 148) with the
mecA promoter mutation and the class B1
mec complex deletion belonged to the same major clonal group, identified
as MCG-2, and harbored the type IV staphylococcal cassette chromosome
mec DNA. There was also a wide range of oxacillin MICs for strains
with wild-type
mecA,
mecI, and
mecR1 sequences, suggesting that
the genetic backgrounds of clinical strains are significant
in determining susceptibility to methicillin.

INTRODUCTION
An understanding of the mechanism causing the variation in susceptibility
to oxacillin (a surrogate compound for methicillin) in clinical
isolates of
Staphylococcus aureus is still far from complete.
One reason for this is that clinical isolates of methicillin-resistant
S. aureus (MRSA) are often clonal but not always isogenic. Methicillin
resistance in
S. aureus is gained as a consequence of acquiring
the
mecA gene, which is located on a 21- to 67-kb-long mobile
element called the staphylococcal cassette chromosome
mec (SCC
mec).
The
mecA gene, together with two regulatory genes,
mecI and
mecR1, constitutes a

4.2-kb
mec complex on the SCC
mec. The
mec complex is considered to be the key element for determining
methicillin resistance in
S. aureus. Although
mecR1 (a signal
transducer gene) and
mecI (the repressor gene) largely control
the expression of
mecA, additional genes may regulate the expression
of
mecA (
1,
2,
12). MRSA strains carrying the
mecA gene that
codes for an altered form of penicillin-binding protein (PBP),
called PBP 2a, have a reduced affinity for beta-lactam antibiotics,
including methicillin. Consequently, MRSA strains that produce
PBP 2a continue to thrive in the presence of beta-lactam antibiotics
(
3).
More than 90% of clinical MRSA isolates carry mecA on their chromosomes (4). Any mutation in the mec complex that may affect the function of these genes is expected to affect methicillin resistance as well. A number of mutations in mecI and mecA from clinical isolates have been described previously. Partial deletions of mecR1 and mecI have also been described. However, there are few data available to make any correlation between the different mutations in the mec complex from large collections of clinical MRSA isolates and the corresponding oxacillin MICs. It has been shown by Rosato et al. that different clinical MRSA strains containing the same C
T mutation at nucleotide (nt) position 202 in mecI produce variable amounts of mecA transcripts, suggesting variable repressor activity in those strains (15). Recently, Katayama et al. (7) showed that multiple mutations in mecA produce high-level resistance against beta-lactams.
In the present report, we describe several new mutations present in the mec complexes of 524 clinical MRSA strains collected over a 10-year period (1989 to 1999) from patients living in rural Wisconsin. We compared the oxacillin MICs for strains with single or multiple mutations and determined if individual mutations arose as random, independent events or were present in strains that were clonally related.
(This work was presented in part at the 2002 International Conference on Emerging Infectious Diseases, Atlanta, Ga.)

MATERIALS AND METHODS
MRSA strains.
The MRSA clinical strains (
n = 524) were collected from 77 health
care facilities that included clinics (64%) and hospitals and
nursing homes (36%) located in northern and central Wisconsin.
The isolates were collected from 1989 to 1999. The frequency
distribution of isolates by study year was as follows: 1989,
1; 1990, 5; 1991, 10; 1992, 44; 1993, 89; 1994, 44; 1995, 62;
1996, 53; 1997, 49; 1998, 95; and 1999, 72. The
S. aureus strains
were identified by colony morphology, Gram staining, and positive
tests for catalase and coagulase. Isolates were considered methicillin
resistant if the oxacillin MIC was

4 µg/ml by the Etest
method according to NCCLS standards (
13).
mec complex PCR and sequencing.
The list of PCR primers used to amplify mecA, mecI, and mecR1, the expected amplicon sizes, and the locations of the genes on the S. aureus chromosome N315 are shown in Table 1. The sequencing primers used were the same as the PCR primers. The nucleotide positions for PCR primers are based on the sequence submitted to GenBank under accession number AP003129. The mec complex segments were amplified by the colony PCR method described below. Each amplicon was purified using a QIAquick PCR purification kit (QIAGEN, Inc., Valencia, Calif.) and then sequenced in either an ABI 377 DNA sequencer or an ABI 3100 genetic analyzer (Applied Biosystems, Foster City, Calif.).
Colony PCR.
Briefly, a few bacterial cells were picked up with a sterile
pipette tip by barely touching the tip to an isolated colony
from a 24- to 48-h-old culture plate. The tip was inserted quickly
into the PCR mixture tube until it touched the bottom of the
tube and then removed quickly to prevent too many cells from
sloughing off the tip. A 50-µl PCR mixture consisted of
25 µl of the HotStarTaq master mixture (QIAGEN, Inc.),
40 pmol each of forward and reverse primers, and 17 µl
of water. The reaction mixture setup was subjected to an initial
incubation at 95°C for 15 min to lyse cells and to activate
the
Taq polymerase, followed by 30 cycles of denaturation at
94°C for 30 s and at 48 to 53.5°C (Table
1) for 40 s
and extension at 72°C for 60 s. A final extension reaction
was carried out at 72°C for 7 min. The PCR products were
resolved on 1.5% agarose gels to determine the quantity and
quality of the amplification products. Occasionally, a second
PCR was done to reamplify the target genes that failed to yield
visible products after the first round of PCR. This was done
by taking 1 to 5 µl from the first amplification reaction
mixture as the template in a PCR setup that was otherwise identical
to the one described above. The number of cycles was reduced
to 20. The products were directly sequenced in either of the
two DNA sequencers (ABI 3100 or ABI 377) with an ABI Prism BigDye
Terminator Cycle Sequencing Ready Reaction kit from Applied
Biosystems.
Statistical analysis of mutations.
The frequency distribution (as a percentage) for single and multiple mutations in the three mec genes was determined. The statistical correlation, if any, between oxacillin resistance and either individual or combined mutations was also determined. The oxacillin resistance of strains with mutations was also compared with that of strains that did not contain any mutations in the mec complex. Since the distribution of the oxacillin MICs was skewed and not normally distributed, the median MIC (mMIC) for strains containing each mutation was used for comparison. Since synonymous mutations would not change the amino acid sequence, they were included in the no-mutation group for comparison. A P value of <0.005 was considered to be statistically significant. All the analyses were performed with SAS software (SAS Institute Inc., Cary, N.C.).

RESULTS
Seven primer pairs were used to amplify the three
mec genes.
Each of the primer pairs amplified a different but overlapping
segment of the three
mec genes. Each primer pair yielded a single
major amplicon of the expected size. The amplicon sizes ranged
from 495 to 870 bp, as shown in Table
1 and Fig.
1.
Identification of a new mec complex type.
At the
mec complex structure level, we identified two groups
of MRSA isolates. The first group was represented by MRSA isolates
that had all three
mec genes with insertions, substitutions,
or short deletions in the
mec complex relative to the same sequence
from the pre-MRSA strain N315 (
5,
10). The second group of isolates
(25.4% of 524 isolates examined) contained a major deletion
in the
mec complex whereby the entire
mecI gene and roughly
45% of the
mecR1 gene, including the penicillin-binding domain,
were deleted (Fig.
2). The deletion was detected upon the repeated
failure of primer sets
mecIF1-
mecIR1 (nt positions 48769 to
49406),
mecR1F3-
mecR1R3 (nt positions 48510 to 49005), and
mecR1F2-
mecR1R2
(nt positions 47706 to 48571) to give any PCR products for that
group of isolates (Table
1). We identified the deletion junction
by sequencing several amplicons from the primer set
mecR1F1-
mecR1R1
(nt positions 46981 to 47765) that covered the entire deletion
region. The deletion site was located at nt position 782 in
the
mecR1 gene. Due to this deletion, the remaining 976 nt of
mecR1, the entire
mecI gene, and 30 nt beyond
mecI were deleted
(Fig.
3). A common set of four nucleotide bases (AACA) was found
on either side of the deletion fragment. The positions were
nt 779 to 782 in
mecR1 and 30 to 33 nt downstream from the ends
of the
mecI genes. We classified this deletion type as a variant
of the class B type (named B1) because we did not detect any
IS
1272 or IS
431 sequences at the deletion junction of
mecR1 (
6,
9,
11).
Polymorphisms in the mec complex in Wisconsin MRSA strains.
Eighteen different mutations that included insertions, substitutions,
deletions, and terminations were identified in the
mec complex
(Table
2). The number of independent mutations identified (excluding
the class B1 type of deletion) in
mecA,
mecI, and
mecR1 were
eight, seven, and two, respectively. The percentages of each
type of mutation shown in Table
2 were based on the number of
isolates tested for that group of mutations in
mec genes. The
corresponding oxacillin MIC range is also listed for each group
of mutations. In 34.7% of the isolates (total examined, 429),
a G

T substitution at position 7 upstream of the
mecA start site
was detected. Only 0.23% of the isolates (total examined, 429)
had a T

A substitution at position 5 upstream of the
mecA start
site. Four additional independent mutations in the
mecA gene
were identified. First,

2.2% of the isolates (total examined,
363) had a substitution mutation in codon 246 (GGA

GAA [G

E]).
Four synonymous mutations were identified in
mecA. They were
at codons 415 (AAT

AAC [N

N], in 1.7%), 442 (AAC

AAT [N

N], in 3.9%),
and 256 (GTT

GTG [V

V], in 13.2%). All isolates that had a T

G
substitution at codon 256 on
mecA also had a frameshift mutation
due to the insertion of a cytosine at the first base of codon
257 (Fig.
2). This insertion created a premature termination
codon at position 260 in
mecA (Table
1). The
mecR1 gene had
two synonymous mutations at codons 117 (AGT

AGC [S

S], in 0.26%)
and 583 (GAA

GAG [E

E], in 89.4%), respectively. Seven mutations
were identified in the
mecI gene. They were three substitutions,
three terminations, and one deletion, as shown in Table
2. Two
substitution mutations were at the N terminus, and the third
mutation was at the C terminus of the deduced amino acid sequence.
The substitutions were at codons 11 (GCA

GTA [A

V], in 0.78%),
31 (ATA

ATG [I

M], in 0.26%), and 121 (AAT

AAA [N

K], in 7.8%).
Three stop-codon-generating mutations were at codons 52 (TTG

TAG,
in 0.26%), 68 (CAA

TAA, in 0.26%), and 115 (GAA

TAA, in 0.78%).
Except for the mutation at codon 68, none of these had been
described previously.
Statistical analysis of the relationship of strains containing major mec mutations with the corresponding oxacillin MICs.
Out of the 18 mutation types, isolates containing the top five
most frequent mutations or combinations of mutations (
n = 104)
in the three
mec genes were chosen for correlation studies with
isolates with no mutations (
n = 192) (Fig.
4). Complete sequence
data were available for the
mec genes of these 296 isolates.
The exclusive mutations tested were a 7-nt-upstream promoter
mutation (7.1%), a cytosine insertion in codon 257 in
mecA (3.04%),
and a class B1
mec complex deletion type (1.0%), whereas the
combination mutations tested were a 7-nt-upstream promoter mutation
plus a class B1
mec complex deletion type (14.2%) and a 7-nt-upstream
promoter mutation plus N121K in
mecI (9.8%). For isolates carrying
any given mutation, the oxacillin MICs had wide ranges. Since
the MICs of oxacillin for different isolates with the same type
of mutation were skewed, we chose the oxacillin mMICs to correlate
with any one type or combination of mutations. The results of
this correlation, which include frequency distribution of isolates
for each type of mutation, mean MICs, and mMICs, are shown in
Fig.
4. The mMICs for isolates with the 7-nt-upstream mutation,
the 7-nt-upstream mutation plus N121K in
mecI, and the 7-nt-upstream
mutation plus the class B1
mec complex deletion were 111, 81,
and 144 µg/ml (mean, 112 µg/ml), respectively, compared
to 241 µg/ml for the isolates with no mutations. Clearly,
the isolates that harbored a 7-nt-upstream mutation had significantly
lower mMICs (mean, 112 µg/ml) than isolates that did not
contain any mutation (
P < 0.0001). This finding suggests
that the promoter-operator region of
mecA plays a more significant
role in the overall resistance to oxacillin in MRSA. The mMICs
for the isolates containing the
mecA mutation involving an insertion
at codon 257 and the class B1
mec complex were 248 and >256
µg/ml, respectively. These values were nearly identical
to the mMICs for the no-mutation group of isolates and also
were statistically not significant.
Clonal relationships of MRSA strains with different mutations in mec genes.
We analyzed the mutation data to see if the mutations were clonal
in nature. The only relationship that could be identified was
the link among the isolates with the 7-nt-upstream mutation,
the class B1
mec complex deletion, and the type IV SCC
mec. Out
of 148 isolates that had the 7-nt-upstream promoter mutation,
85.1% belonged to a pulsed-field gel electrophoresis-based major
clonal group, MCG-2. The remaining 13.9% isolates were distributed
in three minor clonal groups. A major clonal group was defined
as a clonal group that was represented by 5% or more of the
total isolates, and a minor clonal group was one that was represented
by less than 5% of the total isolates (data not shown). Sixty-four
percent of the isolates harboring promoter mutations (
n = 148)
were of the class B1
mec complex type. The remaining isolates
had nondisrupted
mecR1 or
mecI sequences. Interestingly, data
were available for the SCC
mec types and the promoter mutation
of 61 isolates, and 97% of those isolates had the type IV SCC
mec.
There was no obvious clonality to the rest of the mutations.

DISCUSSION
Of the three
mec complex genes, the
mecI gene is reported to
harbor the most mutations, probably because of the negative
selection pressure this gene sustains to make MRSA strains resistant
to methicillin. To some extent, it could also be due to the
fact that this gene was probably more frequently studied than
the other two
mec genes. The previously described mutations
in the
mecI gene are substitutions at nt 22 (A

G), 32 (C

T), 43
(G

T), 116 (A

G), 125 (C

T), 142 (C

T), 152 (G

T), 163 (A

T), 202
(C

T), 260 (T

A), 343 (G

T), and 370 (T

A); insertions of an A at
nt 64, 193, and 250; the insertion of a T at nt 91; and the
deletion of a T at nt position 143 (
9,
15-
17). Several of these
mutations would create either an amino acid substitution or
a premature stop codon in MecI (
9,
15,
17). The C

T change at
nt 202 in
mecI is one of the most commonly reported mutation
types in isolates from the United States, Great Britain, and
some other European countries (
4,
9,
16,
18). However, this
mutation was present in only 0.26% (total examined, 387) of
the Wisconsin MRSA isolates. Since the six other
mecI polymorphisms
reported in this study were novel, this finding suggested that
the Wisconsin MRSA strains might have evolved, both recently
and locally. Besides
mecI, we observed some rare nonsynonymous
mutations in
mecA and synonymous mutations in
mecR1 genes that
were present in less than 1% of the tested isolates (Table
2).
The significance of these rare mutations in methicillin resistance
may be better understood if additional strains containing these
mutations are characterized.
The deletion junction identified in the class B1 mec complex is unique in that it lacks any insertion elements at the junction site. The presence of the four nucleotides (AACA) at the junction site suggests a plausible recombination event. This deletion type was primarily seen in MCG-2 and occasionally in minor clonal groups. The percentage of strains with the mecI-mecR1 deletion ranges from 16 to 73% globally (8, 9, 14, 16, 18). Our data show that 26% of the MRSA isolates collected in Wisconsin from 1989 to 1999 had a variant in the class B mec complex. There was no temporal trend in isolates with any particular mutation, and there was no evidence of any changes in the mutation rate during the study period. The isolates with the class B1 mec complex type of deletion were also interspersed with isolates containing polymorphisms in the mec genes over the study period.
Petinaki et al. (14) have described in their study of isolates from Patras, Greece, that 47% (n = 23) of the isolates for which the oxacillin MIC was low (
128 µg/ml) were negative for the presence of mecI. However, we did not observe any such correlations with high or low oxacillin MICs. Kobayashi et al. have shown that the oxacillin MIC for an MRSA strain with a double mutation, a C
A change in the mecA promoter region and a C
T (Gln68
stop codon) change at position 202 in mecI, is not significantly different from that of an isolate containing a single mutation (9). In a study with a very limited number of strains, there was no correlation between the presence or deletion of mecI and a methicillin MIC of >128 µg/ml (16) We did observe that strains with the 7-nt-upstream promoter mutation in general had lower resistance than the strains with no mutation.
Another significant finding from this study was the observation that there was a high degree of conservation of the amino acid sequence of MecR1. The fact that the mecR1 gene function is conserved at the amino acid sequence level and that the substitutions, mutations, or deletions of mecI have no apparent effect on oxacillin resistance suggests that MecR1 may mediate methicillin resistance through intermediate factors other than MecI, as suggested by others (1). The simultaneous presence in isolates of the 7-nt-upstream mecA mutation and the class B1 mec type of deletion suggests that these two mutations coevolved. The fact that the majority of tested isolates with this combination mutation were present on the type IV SCCmec suggested a limited clonal source in Wisconsin MRSA isolates.
In conclusion, some important observations were made in this study of MRSA isolates from patients living in rural areas. First, several new polymorphisms in the three mec genes of MRSA have been identified. These newly identified polymorphisms can serve as evolutionary markers for MRSA from the midwestern United States and also aid in identifying their subclonal types. Second, the 7-nt-upstream mecA mutation seems to be an important mutation in determining methicillin resistance. Third, the significance of the AACA sequence at the deletion junction in mecR1 needs to be explored further.

ACKNOWLEDGMENTS
S.K.S. acknowledges Sherri Strop for her contribution to
mec complex sequencing for this project as a summer student in 2001.
We also acknowledge Carla Schofield for data management, Mary
Vandermause for help in reading oxacillin MICs, Po-Huang Chyou
for statistical support, William Schwan for critically reading
the manuscript, Graig Eldred for the Fig.
2 graphics, and Alice
Stargardt for assistance in the preparation of the manuscript.
We acknowledge the Marshfield Clinic Research Foundation for its support through a grant-in-aid.

FOOTNOTES
* Corresponding author. Mailing address: Marshfield Clinic Research Foundation, 1000 North Oak Ave., Marshfield, WI 54449. Phone: (715) 389-5363. Fax: (715) 389-3808. E-mail:
shukla.sanjay{at}mcrf.mfldclin.edu.


REFERENCES
1 - Archer, G. L., and J. M. Bosilevac. 2001. Signaling antibiotic resistance in staphylococci. Science 291:1915-1916.[Free Full Text]
2 - Berger-Bachi, B., and S. Rohrer. 2002. Factors influencing methicillin resistance in staphylococci. Arch. Microbiol. 178:165-171.[CrossRef][Medline]
3 - Chambers, H. F., and M. Sachdeva. 1990. Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 161:1170-1176.[Medline]
4 - Hiramatsu, K. 1995. Molecular evolution of MRSA. Microbiol. Immunol. 39:531-543.[Medline]
5 - Ito, T., Y. Katayama, and K. Hiramatsu. 1999. Cloning and nucleotide sequence determination of the entire mec DNA of pre-methicillin-resistant Staphylococcus aureus N315. Antimicrob. Agents Chemother. 43:1449-1458.[Abstract/Free Full Text]
6 - Katayama, Y., T. Ito, and K. Hiramatsu. 2001. Genetic organization of the chromosome region surrounding mecA in clinical staphylococcal strains: role of IS431-mediated mecI deletion in expression of resistance in mecA-carrying, low-level methicillin-resistant Staphylococcus haemolyticus. Antimicrob. Agents Chemother. 45:1955-1963.[Abstract/Free Full Text]
7 - Katayama, Y., H.-Z. Zhang, and H. F. Chambers. 2004. PBP 2a mutations producing very-high-level resistance to beta-lactams. Antimicrob. Agents Chemother. 48:453-459.[Abstract/Free Full Text]
8 - Kobayashi, N., K. Taniguchi, K. Kojima, S. Urasawa, N. Uehara, Y. Omizu, Y. Kishi, A. Yagihashi, I. Kurokawa, and N. Watanabe. 1996. Genomic diversity of mec regulator genes in methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Epidemiol. Infect. 117:289-295.[Medline]
9 - Kobayashi, N., K. Taniguchi, and S. Urasawa. 1998. Analysis of diversity of mutations in the mecI gene and mecA promoter/operator region of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Antimicrobiol. Agents Chemother. 42:717-720.[Abstract/Free Full Text]
10 - Kuroda, M., T. Ohta, I. Uchiyama, T. Baba, H. Yuzawa, I. Kobayashi, L. Cui, A. Oguchi, K. Aoki, Y. Nagai, J. Lian, T. Ito, M. Kanamori, H. Matsumaru, A. Maruyama, H. Murakami, A. Hosoyama, Y. Mizutani-Ui, N. K. Takahashi, T. Sawano, R. Inoue, C. Kaito, K. Sekimizu, H. Hirakawa, S. Kuhara, S. Goto, J. Yabuzaki, M. Kanehisa, A. Yamashita, K. Oshima, K. Furuya, C. Yoshino, T. Shiba, M. Hattori, N. Ogasawara, H. Hayashi, and K. Hiramatsu. 2001. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 357:1225-1240.[CrossRef][Medline]
11 - Lim, T. T., G. W. Coombs, and W. B. Grubb. 2002. Genetic organization of mecA and mecA-regulatory genes in epidemic methicillin-resistant Staphylococcus aureus from Australia and England. J. Antimicrob. Chemother. 50:819-824.[Abstract/Free Full Text]
12 - McKinney, T. K., V. K. Sharma, W. A. Craig, and G. L. Archer. 2001. Transcription of the gene mediating methicillin resistance in Staphylococcus aureus (mecA) is corepressed but not coinduced by cognate mecA and ß-lactamase regulators. J. Bacteriol. 183:6862-6868.[Abstract/Free Full Text]
13 - National Committee for Clinical Laboratory Standards. 1999. Standard M100-S9. Performance standards for antimicrobial susceptibility testing, 9th supplement, vol. 19. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14 - Petinaki, E., A. Arvaniti, G. Dimitracopoulos, and I. Spiliopoulou. 2001. Detection of mecA, mecR1, and mecI genes among clinical isolates of methicillin-resistant staphylococci by combined polymerase chain reactions. J. Antimicrob. Chemother. 47:297-304.[Abstract/Free Full Text]
15 - Rosato, A. E., W. A. Craig, and G. L. Archer. 2003. Quantitation of mecA transcription in oxacillin-resistant Staphylococcus aureus clinical isolates. J. Bacteriol. 185:3446-3452.[Abstract/Free Full Text]
16 - Suzuki, E., K. Kuwahara-Arai, J. F. Richardson, and K. Hiramatsu. 1993. Distribution of mec regulator genes in methicillin-resistant Staphylococcus clinical strains. Antimicrob. Agents Chemother. 37:1219-1226.[Abstract/Free Full Text]
17 - Vandenesch, F., T. Naimi, M. C. Enright, G. Lina, G. R. Nimmo, H. Heffernan, N. Liassine, M. Bes, T. Greenland, M. E. Reverdy, and J. Etienne. 2003. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg. Infect. Dis. 9:978-984.[Medline]
18 - Weller, T. M. 1999. The distribution of mecA, mecR1 and mecI and sequence analysis of mecI and the mec promoter region in staphylococci expressing resistance to methicillin. J. Antimicrob. Chemother. 43:15-22.[Abstract]
Antimicrobial Agents and Chemotherapy, August 2004, p. 3080-3085, Vol. 48, No. 8
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.8.3080-3085.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Stephens, A. J., Huygens, F., Giffard, P. M.
(2007). Systematic Derivation of Marker Sets for Staphylococcal Cassette Chromosome mec Typing. Antimicrob. Agents Chemother.
51: 2954-2964
[Abstract]
[Full Text]
-
Brady, J. M., Stemper, M. E., Weigel, A., Chyou, P.-H., Reed, K. D., Shukla, S. K.
(2007). Sporadic "Transitional" Community-Associated Methicillin-Resistant Staphylococcus aureus Strains from Health Care Facilities in the United States. J. Clin. Microbiol.
45: 2654-2661
[Abstract]
[Full Text]
-
Morgan, W. R., Caldwell, M. D., Brady, J. M., Stemper, M. E., Reed, K. D., Shukla, S. K.
(2007). Necrotizing Fasciitis Due to a Methicillin-Sensitive Staphylococcus aureus Isolate Harboring an Enterotoxin Gene Cluster. J. Clin. Microbiol.
45: 668-671
[Abstract]
[Full Text]
-
Shore, A., Rossney, A. S., Keane, C. T., Enright, M. C., Coleman, D. C.
(2005). Seven Novel Variants of the Staphylococcal Chromosomal Cassette mec in Methicillin-Resistant Staphylococcus aureus Isolates from Ireland. Antimicrob. Agents Chemother.
49: 2070-2083
[Abstract]
[Full Text]
-
Stemper, M. E., Shukla, S. K., Reed, K. D.
(2004). Emergence and Spread of Community-Associated Methicillin-Resistant Staphylococcus aureus in Rural Wisconsin, 1989 to 1999. J. Clin. Microbiol.
42: 5673-5680
[Abstract]
[Full Text]
-
Shukla, S. K., Stemper, M. E., Ramaswamy, S. V., Conradt, J. M., Reich, R., Graviss, E. A., Reed, K. D.
(2004). Molecular Characteristics of Nosocomial and Native American Community-Associated Methicillin-Resistant Staphylococcus aureus Clones from Rural Wisconsin. J. Clin. Microbiol.
42: 3752-3757
[Abstract]
[Full Text]